Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical AnalysisDefense World · Oct 16, 2026
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell LymphomaAccesswire · Oct 15, 2026
Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)Defense World · Sep 27, 2026
Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks TranscriptSeeking Alpha · Sep 16, 2026
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus AcquisitionBenzinga · Sep 16, 2026
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting TherapeuticsAccesswire · Sep 16, 2026Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments.